Bristol-myers Squibb Compnay

Bristol-myers Squibb Holdings Ireland

Fiona McPhee

Paul Michael Scola

Jeffrey Allen Campbell

Andrew Charles Good

Stanley V D'Andrea

Zhizhen Barbara Zheng

Nicholas A Meanwell

Piyasena Hewawasam

Kenneth M Boy

Yong Tu

David J Carini

Barry L Johnson

Jianqing Li

Julie A Lemm

Amy Ripka

Stacey A Voss

Susan E Chaniewski

Amy K Sheaffer

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.

Combinations of hepatitis C virus inhibitors

Macrocyclic peptides are disclosed having the general formula: 

Hepatitis C virus inhibitors

Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I:  wherein Rto R, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

Compounds are disclosed having the general formula: 

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Substituted cycloalkyl P1' hepatitis C virus inhibitors

Growing community of inventors

Wallingford, CT, United States of America

Fiona McPhee